Project Grant R44DK142496
Award Date 9/8/25
Completion Date 9/30/27
Dollars Obligated $1.1M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ithaca, NY 14853, USA
Similar Awards
- The federal Project Grant award of $287,250 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to Persista Bio Inc. to develop the manufacturing process for the cell capsule of the company's O2Line implant system, an advanced oxygenated cell encapsulation system targeting the treatment of type 1 diabetes (T1D). The key products to be...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $509,265.00 to Cornell University to develop a cell-retaining, subcutaneous device that allows blood vessel penetration and establishment of an immunotolerant environment for islet delivery for type 1 diabetes cell replacement therapy. The goal is to create a cell delivery...
- The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health, awarded a $350,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Microvascular Tissues, Inc. The grant supports the evaluation of a microvascular tissue graft treatment in rat models of diabetic peripheral neuropathy. The project aims to assess the ability of this novel microvascular tissue graft to improve...
- This federal Project Grant award of $2,390,830 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) aims to develop scalable and transplantable pancreatic islet organoids with engineered oxygenation. The 4-year project, awarded on September 1, 2025, will be carried out by the University of California, San Francisco. The research seeks to create an islet-supportive microenvironment to improve islet engraftment efficiency for Type 1 diabetes patients undergoing...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $132,270 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Florida. The grant aims to develop a multi-functional 3D-printed biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The project has two key objectives: 1) Identify...
- This $372,067 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of an immune evasive stem cell line for type 1 diabetes regenerative therapy. The grant recipient, Aleutian Therapeutics, Inc., a biotechnology company in Los Angeles, California, is conducting research to create gene editing technologies that enable allogeneic...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $298,364 in funding to Immunoshield Therapeutics Inc. to investigate optimal islet density and dosage within macroencapsulation devices for clinical islet transplantation to treat type 1 diabetes. The research aims to address limitations in current macroencapsulation approaches, such as...